The role of exosomal microRNAs in detecting hepatocellular carcinoma: A systematic review and meta-analysis.

Clin Chim ActaJun 4, 2026 (epub)
Clinical ResearchGastroenterologyOncology (Medical)

Zhihua Zuo, Miyuan Yang, Xiushan Yin et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the diagnostic performance of exosomal microRNAs (miRNAs) in detecting hepatocellular carcinoma (HCC) among 1442 HCC patients, 761 healthy controls, and 1091 chronic liver disease patients. The analysis revealed a pooled area under the curve (AUC) of 0.89, indicating strong diagnostic efficacy for exosomal miRNAs in HCC screening.

Key findings

  • The pooled AUC for exosomal miRNAs in HCC diagnosis was 0.89 (95% CI: 0.86, 0.91).
  • Sensitivity was 0.84 (95% CI: 0.80, 0.88) and specificity was 0.79 (95% CI: 0.71, 0.86).
  • The positive likelihood ratio (PLR) was 4.1 (95% CI: 2.8, 5.9) and the negative likelihood ratio (NLR) was 0.20 (95% CI: 0.15, 0.27).
  • The diagnostic odds ratio (DOR) was 21 (95% CI: 11, 37).

Why it matters

Exosomal microRNAs offer a non-invasive biomarker option for hepatocellular carcinoma, potentially improving early detection and screening strategies in at-risk populations, particularly those with viral hepatitis.

Source

PubMed · PMID 42248317

Published in Clin Chim Acta. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.